Artificial Intervertebral Disc: Cervical Spine
|Original Policy Date
|Last Review Status/Date
Local policy reviewed/1:2015
|Return to Medical Policy Index|
Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.
Several prosthetic devices are currently available for artificial intervertebral disc arthroplasty (AIDA) of the cervical spine. AIDA is proposed as an alternative to anterior cervical discectomy and fusion (ACDF) for patients with symptomatic cervical degenerative disc disease (DDD).
Cervical degenerative disc disease (DDD) is a manifestation of spinal spondylosis that causes deterioration of the intervertebral discs of the cervical spine. Symptoms of cervical DDD include arm pain, weakness, and paresthesias associated with cervical radiculopathy. Disc herniation, osteophytes, kyphosis, or instability that compress the spinal cord result in myelopathy, which is manifested by subtle changes in gait or balance, weakness in the arms or legs, and numbness of the arms or hands, in severe cases. The prevalence of DDD secondary to cervical spondylosis increases with age. An estimated 60% of individuals older than 40 years have radiographic evidence of cervical DDD. By age 65, some 95% of men and 70% of women have at least one degenerative change evident at radiographic examination. It is estimated that approximately 5 million adults in the United States are disabled to an extent by spine-related disorders, although only a small fraction of those are clear candidates for spinal surgery. Cervical DDD is initially treated conservatively using noninvasive measures (e.g., rest, heat, ice, analgesics, anti-inflammatory agents, exercise). If symptoms do not improve or resolve after 6 weeks or more, or if they progress, surgical intervention may be indicated. Candidates for surgical intervention have chronic pain or neurologic symptoms secondary to cervical DDD and no contraindications for the procedure.
Anterior cervical discectomy and fusion (ACDF) is currently considered the definitive surgical treatment for symptomatic DDD of the cervical spine. The goals of ACDF are to relieve pressure on the spinal nerves (decompression) and to restore spinal column alignment and stability. Resolution of pain and neurologic symptoms may be expected in 80% to 100% of ACDF patients. ACDF involves an anterolateral surgical approach, decompression of the affected spinal level, discectomy, and emplacement of either autograft or allograft bone in the prepared intervertebral space to stimulate healing and eventual fusion between the vertebral endplates. A metal anterior cervical plate is attached to the adjoining vertebral bodies to stabilize the fusion site, maintain neck lordosis, and reduce the need for prolonged postoperative brace application that is needed following ACDF without an anterior plate. The choice of bone material for interbody fusion in ACDF has important clinical implications. Allograft bone has several drawbacks, including a small (albeit, unproven) risk of infectious disease transmission; possible immunologic reaction to the allograft, and possible limited commercial availability of appropriate graft material. In contrast, the use of autograft bone in ACDF has potentially substantial morbidities at the harvest site, generally the iliac crest. These morbidities include moderate-to-severe, sometimes prolonged pain; deep infection; adjacent nerve and artery damage; and increased risk of stress fracture. Although there may be slight differences between autograft and allograft sources in the postoperative rate of union, clinical studies demonstrate similar rates of postoperative fusion (90–100%) and satisfactory outcomes for single-level, anterior-plated ACDF, using either bone source. Thus, the choice of graft material involves a trade-off between the risks specific to autograft harvest versus those specific to use of allograft material. Biomechanical modeling studies have suggested that altered adjacent segment kinematics following fusion may lead to adjacent-level DDD; however, the clinical relevance of these changes has not been established.
Artificial intervertebral disc arthroplasty (AIDA) is proposed as an alternative to ACDF for patients with symptomatic cervical DDD. In AIDA, an artificial disc device is secured in the prepared intervertebral space rather than in bone. An anterior plate is not placed to stabilize the adjacent vertebrae, and postsurgical external orthosis is usually not required. It is hypothesized that AIDA will maintain anatomical disk space height, normal segmental lordosis, and physiological motion patterns at the index and adjacent cervical levels. The potential to reduce the risk of adjacent-level degenerative disc disease (DDD) above or below a fusion site has been the major rationale driving device development and use. Disc arthroplasty and ACDF for single-level disease have very similar surgical indications, primarily unremitting pain due to radiculopathy or myelopathy, weakness in the extremities, or paresthesia. However, the chief complaint in AIDA candidates should be radicular or myelopathic symptoms in the absence of significant spondylosis. Patients with advanced spondylosis or hard disc herniations have a separate pathologic condition and require a different surgical approach.
The Prestige ST Cervical Disc (Medtronic) received U.S. Food and Drug Administration (FDA) premarket application (PMA) approval as a Class III device on July 16, 2007. The Prestige ST Cervical Disc is composed of stainless steel and is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following single-level discectomy. The device is implanted via an open anterior approach. Intractable radiculopathy and/or myelopathy should be present, with at least one of the following items producing symptomatic nerve root and/or spinal cord compression as documented by patient history (e.g., pain [neck and/or arm pain], functional deficit, and/or neurologic deficit) and radiographic studies (e.g., computed tomography [CT], magnetic resonance imaging [MRI], x-rays): herniated disc and/or osteophyte formation. The FDA has required the Prestige disc manufacturer to conduct a 7-year post-approval clinical study of the safety and function of the device and a 5-year enhanced surveillance study of the disc to more fully characterize adverse events in a broader patient population.
Another disc arthroplasty product, the ProDisc-C® (Synthes Spine) received FDA PMA approval in December 2007. As with the Prestige ST Cervical Disc, the FDA approval of ProDisc-C is conditional on 7-year follow-up of the 209 subjects included in the noninferiority trial (discussed in Rationale section), 7-year follow-up on 99 continued access subjects, and a 5-year enhanced surveillance study to more fully characterize adverse events when the device is used under general conditions of use. The post-approval study reports are to be delivered to the FDA annually.
The Bryan® Cervical Disc (Medtronic Sofamor Danek) consists of 2 titanium-alloy shells encasing a polyurethane nucleus and has been available outside of the United States since 2002. The Bryan Cervical Disc was approved by the FDA in May 2009 for treatment using an anterior approach of single-level cervical DDD defined as any combination of the following: disc herniation with radiculopathy, spondylotic radiculopathy, disc herniation with myelopathy, or spondylotic myelopathy resulting in impaired function and at least one clinical neurologic sign associated with the cervical level to be treated, and necessitating surgery as demonstrated using CT, myelography and CT, and/or MRI. Patients receiving the Bryan cervical disc should have failed at least 6 weeks of non-operative treatment prior to implantation of the Bryan cervical disc. As a condition for approval of this device, the FDA required the manufacturer to extend its follow-up of enrolled subjects to 10 years after surgery. The study will involve the investigational and control patients from the pivotal investigational device exemption (IDE) study arm, as well as the patients who received the device as part of the continued access study arm. In addition, the manufacturer must perform a 5-year enhanced surveillance study of the BRYAN® Cervical Disc to more fully characterize adverse events when the device is used in a broader patient population.
In more recent years, continued FDA approval requires completion of 2 postapproval studies. One study provides extended follow-up of the premarket pivotal cohort out to 7 years. The second study provides 10-year enhanced surveillance of adverse event data. Continued approval is contingent on submission of annual reports, which include the number of devices sold, heterotopic ossification, device malfunction, device removal, or other serious device-related complications, and analysis of all explanted discs. The following have received FDA approval:
- The PCM [porous-coated motion] Cervical Disc® (NuVasive) received FDA approval in 2012 (P100012). The PCM® is a semi-constrained device consisting of 2 metal (cobalt-chromium alloy) endplates and a polyethylene insert that fits between the endplates.
- Secure®-C (Globus Medical) was approved in 2012 (P100003). The Secure®-C is a 3 piece semi-constrained device with 2 metal (cobalt chromium molybdenum alloy) endplates and a polyethylene insert.
- The Mobi-C® (LDR Spine) received FDA approval in 2013. Mobi-C® is 3 piece semiconstrained device with metal (cobalt-chromium alloy) endplates and a polyethylene insert. The Mobi-C® is approved for 1 (P110002) or 2 level (P110009) disc replacement.
A number of other devices are under study in FDA IDE trials in the United States.
Cervical Disc Prostheses Under Investigation in the U.S.
Prestige® LP (Medtronic)
Primary: dual rails Secondary: endplate ingrowth
FDA IDE clinical trial enrollment complete
Kineflex C® Cervical Artificial Disc Implant (Spinal Motion)
3-piece, metal core
Primary: central keel Secondary: endplate ingrowth
FDA IDE clinical trial complete
CerviCore™ Intervertebral Disc (Stryker)
Primary: dual rails Secondary: endplate ingrowth
3-piece, polyethylene core
Primary: spike fixation Secondary: endplate ingrowth
FDA IDE clinical trial enrollment complete
FDA IDE clinical trial complete
Freedom® Cervical Disc (AxioMed)
FDA IDE trial Recruiting
M6-C (Spinal Kinetics)
Titanium endplates and polymer core
7-piece, with endplates and a nucleus, fibrous annulus, and sheath
FDA IDE trial withdrawn prior to enrollment
IDE: investigational device exemption; MoM: metal-on-metal; MoP: metal-on-polyethlyene; PMA: premarket approval; SS: stainless steel; UHMWPE: ultra-high molecular weight polyethylene
Updates to the regulatory status of these devices can be viewed at online site: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm using the FDA product code “MJO”.
Cervical arthroplasty may be indicated in skeletally mature patients (ages 22-60) for reconstruction of the disc from C3-C7 following a single level complete discectomy for intractable symptomatic cervical disc disease (SCDD). Symptomatic cervical disc disease is defined as neck or arm (radicular) pain that may include functional/neurological deficits.
The following indications for cervical arthroplasty may be considered medically necessary:
-Patients between the ages of 22 and 60 years of age
-Single level symptomatic cervical disc disease -neck or arm (radicular) pain that may include functional/neurological deficits.
-One level disk disease C3-7 confirmed by imaging as follows
- Herniated disk
- Spondylosis (defined by the presence of osteophytes)
-Neck Disability Score >30%
-6 weeks active conservative therapies must be completed including
- Formal active physical therapy program AND
- The use of prescription oral analgesic medications/anti-inflammatories AND
- Interventional steroid injection, if indicated
The following indications are absolute contraindications to cervical arthroplasty and are considered investigational
- Active systemic infections or infections localized to the site of implantation
- Osteoporosis defined as DEXA bone density measured T-score -2.5
- Morbid Obesity, BMI >39
- Marked cervical instability on neutral resting lateral or flexion/extension radiographs; >3mm and/or > 11° of rotational difference to either adjacent level
- Allergy or sensitivity to implant materials
- Severe spondylosis characterized by bridging osteophytes or a loss of disc height > 50 % or an absence of motion (<2°)
- Clinically compromised vertebral bodies at the affected level due to current or past trauma (e.g., radiographic appearance of fracture callus, malunion, or nonunion)
The safety and effectiveness of cervical arthroplasty has not been established with the following conditions and will be considered investigational
- Patients under the age of 22 or over the age of 60
- Not skeletally mature
- More than one vertebral level with SCDD
- Isolated axial neck pain
- Prior fusion surgery at an adjacent vertebral level
- Prior surgery at the level to be treated
- Patients with progressive symptoms and signs of spinal cord/nerve root compression with less than 6 weeks of conservative treatments
- Facet joint disease, arthropathy, or degeneration at the level to be treated
- Neck or arm pain of unknown etiology
- Paget’s disease, osteomalacia, or other metabolic bone disease
- Current medications known to interfere with bone/soft tissue healing (e.g., steroids)
- Rheumatoid arthritis or other autoimmune disease
- Ankylosing spondylitis
- Insulin dependent diabetes mellitus
- Systemic disease including AIDS, HIV, and hepatitis
- Active malignancy
The minimal documents necessary to accurately and expeditiously complete pre-authorization requests for cervical arthroplasty are:
- Specific procedures with CPT/ICD-9 codes and disc levels indicated
- Office notes, including current complete history and physical
- Current medication list
- Current Body Mass Index
- Detailed documentation of extent and response to at least 6 weeks of conservative therapy including physical therapy notes
- Most recent radiology reports for MRI`s, CT`s, etc. Imaging must be performed and read by an independent radiologist. If discrepancies should arise in the interpretation of the imaging, radiological interpretations will supersede.
- Member 50 years of age and under:
- DEXA scan is required if a patient is known to have, or felt to be at risk for, osteopenia/osteoporosis based on history or imaging studies.
- Member 50 years of age and under:
- Flexion-extension films
- Neck Disability Index Questionnaire- Must be signed and dated by the patient
- DEXA scan results (applies to both male and women)
- Members 51 years of age and older:
- DEXA scan report is required for all cervical arthroplasty requests.
- Members 51 years of age and older:
- Medical clearance reports (as indicated)
22856 Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), single interspace, cervical
22861 Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
22864 Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
There are add-on CPT category III codes for implantation in additional interspaces: 0092T: Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), each additional interspace, cervical (List separately in addition to code for primary procedure) (code deleted 12/31/14)
22858 Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level cervical (List separately in addition to code for primary procedure)
Also effective January 1, 2015, there is a new CPT category III code for three or more levels:
0375T Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), cervical, three or more levels
There are add-on CPT category III codes for these procedures in additional cervical interspaces: 0095T: Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace; cervical (List separately in addition to code for primary procedure) 0098T: Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace; cervical (List separately in addition to code for primary procedure)
Prior to 2015, there was a CPT category III code for performance of this procedure in additional interspaces:
0092T: Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), each additional interspace, cervical (List separately in addition to code for primary procedure)
This policy was developed in 2006 and revised based on TEC Assessments in 2007, 2009, 2011, and 2013,(1-4) with additional updates of the literature using the MEDLINE database (most recently performed through November 20, 2013). The 2009 TEC Assessment reviewed the 2-year follow-up of the trials for the U.S. Food and Drug Administration (FDA)‒approved Prestige ST discs(5) and ProDisc-C,(6) concluding that artificial intervertebral disc arthroplasty (AIDA) did not meet TEC criteria due to insufficient evidence.(2) Neither the Prestige nor ProDisc-C trial provided adequate direct evidence over the relevant follow-up period (suggested to be 5-7 years) on subsequent adjacent-level degenerative disc disease (DDD) in control and investigational group patients. The 2011 and 2013 TEC Assessments reviewed midterm small (<10% of the scale) and not considered to be clinically relevant. No significant difference between AIDA and fusion was found for adjacent level surgery.
Prestige Cervical Disc
The Prestige disc received FDA marketing approval in 2007. Information on the Prestige cervical disc is available from a published report of the pivotal trial and from Medtronic’s premarket approval (PMA) application to FDA.(5,8) These documents report results from a randomized study of anterior cervical fusion (with allograft bone and plate stabilization) versus the artificial cervical disc for patients with nonaxial pain and other symptoms secondary to radiculopathy or myelopathy that did not improve with a minimum 6 weeks of conservative therapy. The study was designed as a randomized, nonblinded noninferiority trial with a 10% margin. Results for 137 investigational and 148 control patients who were evaluated at 2 years postsurgery were presented to FDA in the PMA application. These patients represented about half of the total population (276 and 265, respectively), while the peer-reviewed paper reported on about 75% of cases.
Three primary outcome variables were used in the Prestige trial: the Neck Disability Index (NDI), neurologic status, and functional spinal unit (FSU) height. The NDI is a validated multidimensional instrument that measures the effects of pain and disability on a patient’s ability to manage everyday life.(9) It is a modification of the Oswestry Low Back Pain Index, based on the response to 10 questions that focus on neck pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation. The response to each question ranges from 1 to 5, with a lower numeric score representing a better pain and disability status for that variable. A total NDI score is obtained by adding individual question scores and dividing by the maximum total of 50, if all questions are answered. Therefore, NDI scores range from 0% to 100%, with a lower percentage indicating less pain and disability. The neurologic status is a composite measure of motor function, sensory function, and deep
tendon reflexes. It is used to judge if patients are within normal parameters for those categories based on physiologic measurement. Neurologic success in the Prestige trial was based on postoperative maintenance or improvement of condition as compared to preoperative status for each component. The anterior FSU height is a radiographic measure of interdiscal space. Comparison of the immediate postoperative FSU height with the 6-week postoperative value shows whether or not the disc space has decreased, which indicates that graft or device subsidence has occurred. Secondary outcome measures include the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Mental and Physical Component Summary scores, neck and arm pain status, patient satisfaction, patient global perceived effect, gait assessment, foraminal compression test, adjacent level stability and measurements, return to work, and physician’s perception.
Both data sources for the Prestige disc trial showed equivalent results. Thus, 81% of both groups showed at least a 15-point improvement for the NDI, demonstrating noninferiority to fusion but not superiority. Similarly, the FSU height measure also demonstrated evidence of noninferiority but not superiority. Neurologic status showed noninferiority and statistical superiority for the disc compared to fusion. This contributed to the overall success composite end point demonstrating superiority for the disc compared to fusion. While maintained or improved neurologic status was more frequent following AIDA, it was unclear whether examiners were blinded. The majority of secondary outcome measures for the disc were deemed noninferior to ACDF, but none was statistically superior. Perioperative results and adverse events were
similar in both groups, with very few serious complications.
Sixty-month follow-up of participants in this clinical trial were reported by Burkus et al in 2010.(10) All participants were followed up in this FDA-regulated postapproval study. Outcomes at 60 months were reported on approximately half of the original randomized controlled trial (RCT) participants. The majority of the remaining patients had not yet reached that point in their follow-up, rather than being lost to followup. About 18% of all participants were actually lost to follow-up at 60 months. The NDI improved by 38.4 points for the Prestige disc compared to 34.1 for ACDF (p=0.022). For most other clinical outcomes, the Prestige disc was similar to ACDF, with no significant difference between groups in improvement in neck pain score (56.0 vs 52.4) or arm pain score (52.5 vs 47.7, both respectively). There was a trend for greater neurologic success in the Prestige disc group (95% vs 89%, p=0.051). Need for additional surgery was similar between the 2 procedures, and there was no significant difference in the percentage of patients requiring adjacent-level surgery (2.9% vs 4.9% for ACDF). No implant migration was observed at up to 60 months. Bridging bone was observed in 3 of 94 patients (3.2%) with the Prestige disc.
Murrey et al reported 2-year results from the pivotal FDA randomized noninferiority trial to determine the safety and efficacy of ProDisc-C in comparison with ACDF.(11) In this trial, 103 patients received the ProDisc-C implant and 106 were treated with fusion; participants were blinded to intervention until following surgery. Follow-up between 6 weeks and 2 years was reported to be 85% in the summary of safety and effectiveness data presented to FDA.(12) Reasons for the loss to follow-up were not described but appear to have included 2 patients in the ProDisc-C group who had the implant removed and 5 patients in the fusion group who had undergone additional surgical procedures to modify the original implant. Non-inferiority was achieved for the FDA-defined combined end point of neurologic examination, NDI, adverse events, and device success, with 72% of ProDisc-C and 68% of fusion patients achieving success in all 4 component end points. Clinical outcomes at 24 months’ follow-up were reported to be similar in the ProDisc-C and fusion groups for the following components: neurologic success (91% vs 88%), neck disability index (21.4 vs 20.5 points), reduction in pain scores (eg, 46-mm vs 43-mm reduction in neck pain on a visual analog scale [VAS]), and patient satisfaction (83 mm vs 80 mm, respectively).
Four-year interim follow-up of participants in this clinical trial were reported by Delamarter et al 2010.(13) All participants in the clinical trial were followed up in this FDA-regulated postapproval study. At 48 months, follow-up rates for ProDisc-C and ACDF were 63% and 46.2% respectively. It was not reported what proportion of these patients had not yet reached 48 months postsurgery or were truly lost to followup at that time point. Also included in this report was 24-month follow-up on 77% of 136 continued access patients who received the ProDisc-C after the clinical trial. Clinical outcomes were similar between the 3 groups, with point estimates in favor of ProDisc-C. The NDI at 48 months was 20.3 for ProDisc-C versus 21.2 for ACDF. Neurologic success was achieved in 88.9% of ProDisc-C patients in comparison with 74.4% of ACDF patients (p=0.067). There was a cumulative incidence of additional surgeries of 2.9% (3 patients) in the ProDisc-C group and 11.3% (12 patients) in the ACDF group. Two patients were converted to fusion with removal of the device; 1 patient had decompression with supplemental fixation without removal of the device. At 48 months, 5 ProDisc-C patients (7.7%) were found to have bridging bone.
Five-year results of this trial were published in 2013 with follow-up rates of 72.7% for ProDisc-C and 63.5% for ACDF.(14,15) Outcomes on the NDI were found to be similar (50%-60% improved), along with VAS for arm pain (18 for both groups) and scores on the SF-36. VAS for neck pain was modestly improved with ProDisc-C compared to ACDF (21 vs 30), although the proportion of patients who achieved a clinically significant improvement in neck pain was not reported. There was a lower percentage of
patients with ProDisc-C who had secondary surgery at either the index or adjacent level (2.9% vs 14.5%).
Nabhan et al reported 1-year clinical and radiologic results of 49 patients randomized to receive a ProDisc-C artificial disc or fusion.(16) Measurements taken at 3, 6, 12, 24, and 52 weeks showed a decrease in segmental motion at the index level in both groups over the first 12 weeks after surgery; at 52 weeks, segmental translation (xyz axis) was about 1 mm greater in the ProDisc-C group. Clinical results were similar in the 2 groups, with a 70% reduction in neck pain and 86% reduction in arm pain in the
ProDisc-C group and a 68% reduction in neck pain and 83% reduction in arm pain in the ACDF group. As noted by the authors, longer follow-up is needed to determine the effect of this implant on cervical motion and stress at adjacent levels.
Bryan Cervical Disc
Two- and 4-year results have been published from the IDE trial for the Bryan disc.(17,18) The trial employed inclusion/exclusion criteria and a composite outcome identical to the ProDisc-C trial. A total of 582 patients were randomized to the Bryan disc (n=290) or ACDF (n=292). Thirty-seven patients declined surgery in the AIDA group; 80 patients declined surgery in the ACDF group. Twelve patients crossed over from AIDA to ACDF, 1 crossed over from ACDF to AIDA, and 2 patients were excluded from ACDF due to protocol violations, leaving 242 patients who underwent AIDA and 223 who underwent ACDF. In the AIDA and ACDF arms, mean age (44.4 and 44.7 years), sex (45.5% and 51.1% men) and NDI scores (51.4 and 50.2, all respectively) were similar. All but 1 patient who underwent AIDA and 3 patients in the ACDF arm had documented neurologic abnormalities. After 2 years’ follow-up, data were available for 230 (95%) patients from the AIDA group and 194 (87%) who underwent ACDF. The overall success outcome was achieved more often after AIDA (82.6% vs 72.7%), with a mean 4.1-point greater improvement in the NDI scores. As measured by the composite end point, AIDA was superior to ACDF. At 24 months, neck pain scores were lower following AIDA, while other secondary outcomes were similar. Adverse event rates were similar in the 2 arms—1.7% in AIDA and 3.2% in ACDF arms, requiring revision.
In 2011, 4-year follow-up from the IDE trial was reported for 181 patients (75% of 242) who received the Bryan disc and 138 patients (62% of 223) who underwent ACDF.(18) It was reported that 25% of AIDA and 38% of the ACDF patients failed to return for follow-up at 48 months, due in part to FDA and institutional review board approvals and the need for additional patient consent for the continuation study. Overall success was defined as an improvement of equal to or greater than 15 points in the NDI, neurologic improvement, no serious adverse events related to the implant or surgical implantation procedure, and no subsequent surgery or intervention that would be classified as a treatment failure. The 4-year overall success rates were significantly greater in the Bryan (85.1%) than the ACDF (72.5%) group. This finding was driven largely by differences in the NDI success (90.6% of arthroplasty and 79.0% of ACDF). Neurologic success rates were not different between the groups. Arm pain improved from a baseline of 71.2 in both groups to 16.6 for the Bryan disc and 22.4 for ACDF, the difference between groups was statistically significant. The improvement in neck pain scores was also significantly better in the Bryan disc group (from 75.4 to 20.7) compared to patients with fusion (from 74.8 to 30.6). Improvement in the SF-36 physical component score was also significantly greater in the arthroplasty group (15.8 vs 13.1). There was no significant difference in additional surgical procedures at either the index (3.7% Bryan, 4.5% ACDF) or adjacent (4.1% Bryan, 4.1% ACDF) levels. FDA-required follow-up will continue for 10 years after the index surgery.
In the discussion of this article, the authors comment that failure of other joint arthroplasty prostheses does not typically occur until at least 5 to 10 years postoperatively and that spinal arthroplasties also need to have serial assessments to determine whether complications such as wear-related failures, device fatigue, or spinal instability have developed. They conclude that as with any motion-sparing device, “longer-term follow-up is necessary for assessment of potential problems related to bearing surface wear.”
A post hoc subgroup analysis of 199 participants with myelopathy from the Prestige ST (n=111) and Bryan (n=88) trials found similar improvement in postoperative neurologic status and gait at 24 months (Prestige ST: AIDA 90% [95% confidence interval (CI), 79% to 97%] and ACDF 81% [95% CI, 65% to 92%]; Bryan: AIDA 90% [95% CI, 76% to 97%] and ACDF 77% [95% CI, 76% to 97%]). (19) The authors noted that "although short-term results of cervical disc arthroplasty appear encouraging, studies with at least five to ten years of follow-up are required before cervical disc replacement can be viewed as a standard treatment for disc-based cervical myelopathy."
In 2010, Goffin et al reported 4- and 6-year follow-up from Phase I and Phase II trials of the Bryan disc.(20) The total potential patient population for long-term follow-up was 98 patients (89 with 1-level and 9 with 2-level); 59 of the patients were at least 6 years postoperative. Although 4 patients from the Phase I study declined to participate in the extended follow-up study, their results were included in the safety data. Mean neck pain at 4 and 6 years postoperatively was 2.2 and 2.0, respectively. Mean arm pain at 4 and 6 years was 2.4 and 2.3, respectively. Six patients experienced events that were believed to be related to the device, including minor device migration, device removal, hoarseness, and vocal cord paralysis, while 3 of the 6 cases involved pain or neurologic symptoms. The prosthesis was removed from 1 patient at 6 years after the index surgery because of progressive spinal cord compression due to recurrent posterior osteophyte formation. About 90% of patients were classified as having excellent or good outcomes at 4 and 6 years. The success rate estimated by Kaplan-Meier analysis was 94% at 7 years following surgery.
Two-level Bryan Cervical Disc
In 2009, Cheng et al reported 2-year follow-up from an RCT of the Bryan disc versus ACDF with autograft in 65 patients with 2-level disc disease.(21) One patient from the arthroplasty group and 2 patients from the ACDF group were lost to follow-up. Neck pain and arm pain measured by VAS tended to be better in the Bryan group (1.8 and 1.9, respectively) than the ACDF group at 12-month follow-up (2.5 and 2.4, respectively) and continued to improve at 2-year follow-up (Bryan, 1.5 and 1.4; ACDF, 2.6 and 2.7, respectively). NDI and SF-36 Physical Component Summary scores were also significantly better in the Bryan group at both 12- and 24-month follow-up. These results support the short-term safety of the Bryan disc in 2-level disc disease; longer-term results are needed to evaluate the safety and efficacy of this device in comparison with ACDF for 2-level disc disease.
In 2011, Coric et al reported the 24-month pivotal multicenter randomized IDE trial of the metal-on-metal Kineflex-C artificial disc (n=136), compared to ACDF performed with allograft and anterior plate (n=133).(22) There were no significant differences between the Kineflex-C and ACDF groups for operative time, blood loss, length of hospital stay, or reoperation rate at the index level. The overall success rate was significantly greater in the Kineflex-C group (85%) compared with the ACDF group
(71%). (Overall success was defined as a composite measure of neurologic evaluation, >20% improvement in NDI, no device failure, no reoperation at the index level, and no major device-related adverse event.) There were 6 index-level reoperations (5%) in the Kineflex-C group, including 1 case of metal sensitivity and 2 for device migration. There were 7 index-level surgeries (7.6%) in the ACDF group, including 3 for pseudarthrosis and 4 for instrumentation failure (removal or revision of the original anterior plate and screw construct). There was no significant difference between groups in VAS pain scores or NDI. Although fewer Kineflex-C patients showed severe adjacent-level radiographic changes (9% vs 24.8%), there was no significant difference between the groups in the adjacent-level reoperation rate (7.6% for the Kineflex-C group and 6.1% for the ACDF group) at short-term follow-up.
The need for longer-term studies remains to assess device failure and other long-term complications. An accompanying editorial notes that while the 24-month IDE trials of artificial discs have been well done, and these new motion-saving mechanical devices may potentially be better than ACDF, a number of complications can occur with arthroplasty that include dislodgement, vertical vertebral body fracture, device failure, and heterotopic ossification.(23) Given that no mechanical device has an infinite lifespan, and we do not know the failure rate, timeframe, or consequences of failure of cervical arthroplasty devices, a longer period of scientific scrutiny was advised to determine the real efficacy of artificial cervical discs.
Mobi-C is the only artificial disc that is approved for 1- or 2-level cervical disc disease. The 1-level Mobi-C trial randomized 169 patients to receive AIDA and 87 to ACDF.(24) Patient characteristics were generally similar to the other trials. Patient with multilevel disease or previously treated cervical disease were excluded from the trial. At 24 months, the follow-up rate was 93%. Designed as a noninferiority trial, noninferiority criteria were met for NDI mean improvement, percent NDI success (≥15-point
improvement), and overall success. The overall protocol-specified success rate was higher in the Mobi-C group than the ACDF group (73.7% vs 65.3%), which met noninferiority criteria but did not meet superiority criteria. Cumulative subsequent surgical interventions at the index level were numerically lower in the AIDA group than the ACDF group (1.2% vs 6.2%).
Results from the 2-level Mobi-C IDE trial were reported by Davis et al in 2013.(25) In this noninferiority trial, 225 patients received the Mobi-C device at 2 contiguous levels and 105 patients received 2-level ACDF. The follow-up rate was 98.2% for the AIDA group and 94.3% for the ACDF group at 24 months. Both groups showed significant improvement in NDI score, VAS neck pain, and VAS arm pain from baseline to each follow-up point, with Mobi-C meeting the noninferiority margin. Subsequent testing for superiority showed that AIDA patients had significantly greater improvement than ACDF patients in NDI at all time points and had higher NDI success rates (78.2% vs 61.8%) and overall success rates (69.7% vs 37.4%). AIDA resulted in significantly greater improvement in VAS neck pain at 3 and 6 months
postoperatively but not at 12 or 24 months. Arm pain scores did not differ between the groups. The Mobi-C group had a lower incidence of device-related adverse events (16.7% vs 34.3%), serious adverse events (23.9% vs 32.4%) and a lower reoperation rate (3.1% vs 11.4%). At 24 months, adjacent-level degeneration was observed in the superior segment in 13.1% of AIDA patients and 33.3% of ACDF patients. Adjacent-level degeneration was observed in the inferior segment in 2.9% of AIDA patients and
18.1% of ACDF patients.
Huppert et al compared outcomes between single- (n=175) and multilevel (2-4 levels, n=56) AIDA with the Mobi-C device in a prospective multicenter study from Europe. (26) The age of the patients was significantly higher, and the time since symptom onset was significantly longer in the multilevel group. At 2 years, there was no significant difference between groups for the radicular VAS, cervical VAS, or NDI. Range of motion was similar in the 2 groups. The overall success rate was 69% for the single-level group and 69% for the multilevel groups. There was a trend for more patients in the single-level group to return to work (70% vs 46%), and for the return to work to occur sooner (4.8 months vs 7.5 months). A similar percentage of patients underwent adjacent-level surgery (2.3% for single-level and 3.6% for multilevel).
PCM Cervical Disc
Results of the 2-year FDA-regulated multicenter randomized noninferiority trial of the PCM Cervical Disc were reported by Phillips et al in 2013.(27) The investigator and surgical staff were not blinded to treatment assignment, and patients were informed of the treatment assignment after surgery. Of the 416 patients who were randomized (224 PCM, 192 ACDF), 340 (82%, 189 PCM and 151 ACDF) were per protocol for the 24-month primary end point of overall success. Overall success was defined as at least 20% improvement in NDI; absence of reoperation, revision, or removal; maintenance or improvement in neurological status; and absence of radiographic or major complications during the 24-month follow-up period. At 24 months, overall success was 75.1% in the PCM group and 64.9% in the ACDF group, which met both the noninferiority and superiority criteria. There was a trend toward a greater neurological success rate in the PCM group (94.7%) compared with ACDF (89.5%, p=0.10). There was no significant difference between the groups for VAS pain scores, SF-36 component scores, or implant- or surgeryrelated adverse events (5.2% PCM vs 5.4% ACDF). Patients with prior fusion were included in this study. Overall success for the 2 subgroups in this analysis was similar (65.4% PCM and 64.3% ACDF).
The FDA-regulated SECURE-C trial was a multicenter un-blinded noninferiority trial with151 patients randomized to receive AIDA and 140 patients randomized to ACDF.(28) Patients with multilevel disease or previously treated cervical disease were excluded from the trial. Overall success was defined by FDA as a 15-point or more improvement in NDI; absence of reoperation, revision, or removal; stable or improved neurologic status, and absence of radiographic or major complications during the 24-month follow-up period. At 24 months, the follow up rate was 87%. Noninferiority criteria were met for NDI mean improvement, percent NDI success (89.2% vs 84.5%), neurologic success (96.0% vs 94.9%), and overall success (83.8% vs 73.2%, AIDA vs ACDF, all respectively) using FDA-defined criteria. The overall success rate as specified in the protocol at 24 months (>25% improvement in NDI, no removals and no complications) was also higher in the SECURE-C group than the ACDF group (90.1% vs 71.1%), which met both noninferiority criteria as well as superiority criteria. Cumulative secondary surgical interventions at the treated level were lower in the AIDA group than the ACDF group (2.5% vs 9.7%).
Adjacent Segment Degeneration
A key question is whether cervical disc arthroplasty reduces adjacent segment degeneration, which is the hypothetical advantage of motion-preserving artificial discs. In a 2010 report, Jawahar et al evaluated the incidence of adjacent segment degeneration in 93 patients with 1- or 2-level cervical DDD who had participated in 1 of 3 FDA-regulated RCTs (Kineflex-C, Mobi-C, or Advent Cervical Disc).(29) ACDF was performed using the modified Smith Robinson technique using cortical bone allograft. VAS pain scores, NDI, and cervical spine radiographs were collected at 6 weeks and at 3, 6, 12, 24, 36, and 48 months after surgery. Success was defined as a composite of reduction by more than 30 points in both VAS (100- point scale) and NDI, absence of neurologic deficits, and no further intervention at the index level. Patients developing new complaints pertaining to cervical spine were worked up for possible adjacent segment disease with repeat magnetic resonance imaging (MRI) of the cervical spine and electrophysiologic studies. Only those patients who demonstrated clinical and radiologic stigmata of adjacent segment disease, and received active intervention for its management, were included in the statistical analysis.
At a median follow-up of 37 months (range, 24-49) 73.5% of ACDF and 71% of arthroplasty patients satisfied the criteria for clinical success. The median symptom-free survival period was 39.8 months for ACDF and 38.1 months for arthroplasty patients. There was no statistical difference between the groups for VAS or NDI at the final follow-up. The mean improvement in NDI was 43 points for ACDF and 45 points for arthroplasty; the mean improvement in VAS was 62 points for ACDF and 62 for arthroplasty. At final follow-up, 16% of arthroplasty patients and 18% of ACDF patients were treated for adjacent segment degeneration; these rates were not significantly different. The mean period of freedom from adjacent-level disease was 38 months for both groups.
In 2012, the same group of investigators published a report that included 170 patients (57 ACDF and 113 arthroplasty, with likely overlap in patients from the previous study) with a median follow-up of 42 months (range, 28-54).(30) As in the earlier report, there was no significant difference in adjacent-level disease between ACDF and arthroplasty patients (14% vs 17%, respectively). The mean period of freedom from adjacent-level disease was 46 months after ACDF and 49 months after total disc arthroplasty. Osteopenia and lumbar DDD were found to significantly increase the risk of adjacent level disease.
In 2010, Coric et al reported outcomes from 98 patients with 1- or 2-level cervical disc disease who had participated in 1 of 3 IDE studies (Bryan, Kineflex/C and Discover cervical disc).(31) Patients were evaluated with neurologic examinations, radiographs, and clinical outcome indices at 1, 3, 6, 12, 24, 36, 48, and 60 months. A minimum follow-up of 24 months (range, 24 to 67) was available for 90 patients (53 arthroplasty and 41 ACDF). Clinical success, defined as a composite measure consisting of 5 separate components (neurologic, 20% improvement in NDI, no adverse events, no reoperation at the index or adjacent level, no narcotic usage at 24-month follow-up) was achieved in 85% of arthroplasty and 70% of ACDF patients (p=0.035). Overall, angular motion was improved by 0.91° in the arthroplasty group and reduced by 7.8° in the ACDF group. In the arthroplasty group, there was a 5.6% incidence of bridging heterotopic ossification (3 cases). There were a similar number of reoperations, with 4 (7.5%) in the combined arthroplasty group (1 at the adjacent level) and 3 (8.1%) in the ACDF group (all at the adjacent level). A 2013 report from this group reported minimum 48-month follow-up (range, 48-108) of 74 patients who had received a Bryan or Kineflex cervical disc.(32) There were no significant differences between the
groups in the mean NDI or median VAS scores. There were 3 reoperations (7.3%) at the index (n=1) or adjacent levels (n=2) in the AIDA group and 1 (3%) adjacent level reoperation in the ACDF group.
Results on adjacent level degeneration from the 2-level Mobi-C IDE trial were reported in 2013 from 225 patients who received the Mobi-C device at 2 contiguous levels and 105 patients who received 2-level ACDF. (25) At 24 months, adjacent-level degeneration was observed in the superior and inferior segments in 13.1% and 2.9% of AIDA patients, respectively. Adjacent-level degeneration was observed in the superior and inferior segments in 33.3% and 18.1% of ACDF patients, respectively.
Maldonado et al evaluated adjacent-level degeneration in a prospective cohort study of 85 patients treated with AIDA and 105 treated with ACDF for single-level DDD.(33) The rationale for treatment allocation was not described. At 3 years after surgery, radiographic evidence of adjacent-segment disease was found in 10.5% of patients in the ACDF group and in 8.8% of subjects in the AIDA group (not significantly different). There was no significant difference between groups in VAS arm pain or NDI.
Reports of device failure may emerge with increased use of artificial discs and longer follow-up. One case report describes failure of a Bryan cervical disc due to a fatigue fracture of the flexible polyether urethane sheath at 8 years after implantation.(34) Degradation of the sheath, including surface fissures and full-thickness cracks, has been observed in 27% of retrieved Bryan discs.(35) One case of anterior migration of the Mobi-C disc was reported. (36) Another case was reported of fragmented fracture of the ceramicon-ceramic Discocerv® Cervidisc Evolution at 1 month after implantation.(37) This artificial disc is not available in the U.S.
A lower incidence of dysphagia has been reported with cervical arthroplasty in comparison with ACDF.(38) As part of the IDE trial for the porous-coated motion (PCM) device, patients who underwent arthroplasty (n=151) or ACDF (n=100) self-reported dysphagia severity using the validated Bazaz Dysphagia Score. The arthroplasty group showed a significantly lower incidence of dysphagia at all time points (6 weeks and 3, 6, 12, and 24 months after surgery). For example, at the 6-week follow-up,
moderate-to-severe dysphagia was reported in 18.7% of arthroplasty patients compared with 37.3% of ACDF patients, while at 12-month follow-up, moderate-to-severe dysphagia was reported in 4.3% of arthroplasty patients compared with 13.1% of ACDF patients.
A meta-analysis of heterotopic ossification (McAfee Grade 3-4) after AIDA was published by Chen et al in 2012.(39) Included in the meta -analysis were 8 studies (617 patients). The pooled prevalence of any heterotopic ossification was 44.6% at 12 months after AIDA and 58.2% at 24 months after AIDA. The pooled prevalence of advanced heterotopic ossification was 11.1% after 12 months and 16.7% after 24 months. Although no publication bias was identified, there was significant heterogeneity in study results.
The largest study included in the meta-analysis evaluated rates of heterotopic ossification in 170 patients who had undergone cervical arthroplasty with 1 of 3 cervical discs (81 Bryan, 61 Mobi-C, 28 ProDisc-C) and had at least 12 months of follow-up.(40) Heterotopic ossification was found in a total of 40.6% of patients; the median time without heterotopic ossification was 27.1 months. Heterotopic ossification occurred in 21% of Bryan patients, 52.5% of Mobi-C, and 71.4% of ProDisc-C patients. This study had several limitations. First, the investigators could not completely discriminate whether the newly developed bone was true heterotopic ossification or a bone mass from normal fusion of the prosthesis to bone. There was also a possibility of underestimating posterior or lateral heterotopic ossification due to limited sensitivity of plain radiographs. In addition, clinical outcomes were not assessed.
Tu et al assessed heterotopic ossification in a series of 36 patients (52 levels) who had received total disc replacement with the Bryan cervical disc and had completed clinical and radiological evaluations.(41) Heterotopic ossification was observed in computed tomography (CT) images in 50% of the patients at a mean of 19 months’ follow-up. However, only 2 treated levels (3.8%) showed a loss of segmental motion (<2°) by dynamic radiography. At a mean of 27 months’ follow-up, clinical evaluation indicated a similar clinical success rate in patients who had heterotopic ossification compared with those who did not (94.4% in both groups).
Progressive spinal cord compression due to osteophyte formation has been observed with cervical disc arthroplasty.(20)
The evidence on adverse effects of cervical AIDA raises questions on the overall risk/benefit ratio for these devices. The potential to reduce adjacent level DDD has been the major rationale driving device development and use of AIDA. Evidence to date has not demonstrated a reduction in adjacent level disease with use of artificial cervical discs.
The rates of device failure and the need for reoperations due to device failure or malfunction are not welldefined. Reports of device failure that occur at time periods longer than the average follow-up in the clinical trials highlights the need for longer term studies to further define these adverse events.
Heterotopic ossification could potentially have a negative impact on the goal of mobility with AIDA. Studies to date indicate a high rate of heterotopic ossification at short-term follow-up. Longer follow-up with clinical outcome measures is needed to evaluate the clinical significance of heterotopic ossification following AIDA.
The first reported case of a delayed hypersensitivity reaction to metal ions after disc arthroplasty was in 2009.(42) Although no intracellular or extracellular metal alloy particles were detected in the tissue, the lymphocyte-dominated response was thought to be similar to reactions reported in patients with metal-onmetal hip prostheses. The patient had complete resolution of symptoms following implant removal and fusion. In 2011, Guyer et al reported 4 cases of a lymphocytic reaction to a metal-on-metal artificial disc (1 Kineflex-C cervical disc and 3 lumbar) that required revision.(43) The mode of failure was determined to be compression of neural tissue or other adjacent structures by a soft tissue mass. Three patients had a good outcome after the explantation and revision surgery; 1 patient continued to have residual symptoms related to the neural compression caused by the mass. No hypersensitivity reactions have been reported from devices with a polyethene/polyurethane insert or from Prestige stainless steel implants, however, periprosthetic tissue explanted after 1 to 7 years commonly showed focal metallosis.(35)
Clinical Input Received through Physician Specialty Societies and Academic Medical Centers
In response to requests, input was received from 2 physician specialty societies and 2 academic medical centers while this policy was under review for March 2009. While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted. The clinical input obtained disagreed with the conclusion that AIDA is investigational.
After 2 years of follow-up, trials of all the artificial cervical discs met noninferiority criteria as measured by the NDI and overall success composite outcome. Longer term outcomes have only been reported on 3 of the devices (Prestige ST, ProDisc-C, and Bryan disks). The reports of long-term outcomes of these devices lack optimal follow-up rates. The trial results are consistent with continued noninferiority of AIDA for all devices and lower cumulative reoperation rates at 4 to 5 years, but uncertainty remains because of the less than optimal follow-up rates. In addition, the reports of adverse effects of cervical artificial intervertebral disc arthroplasty (AIDA) raise questions on the overall risk/benefit ratio for these devices.
- The potential to reduce adjacent-level degenerative disc disease has been the major rationale driving device development and use of AIDA. Evidence to date has not consistently demonstrated a reduction in adjacent level disease with use of artificial cervical discs.
- The rates of device failure and the need for reoperations due to device failure or malfunction are not well-defined. Reports of device failure that occur at time periods longer than the average follow-up in the clinical trials highlights the need for longer term studies to further define these adverse events.
- Heterotopic ossification could potentially have a negative impact on the goal of mobility with AIDA. Studies to date indicate a high rate of heterotopic ossification at short-term follow-up. Longer follow-up with clinical outcome measures is needed to evaluate the clinical significance of heterotopic ossification following AIDA.
At the present time, there is insufficient evidence to determine the impact of cervical arthroplasty devices on clinical outcomes over the long term. Results of trials that report 4- to 5-year outcomes are consistent with continued noninferiority of AIDA, but uncertainty remains as to whether the benefits of these devices outweigh the risks. Evidence to date has not shown a consistent beneficial effect of any cervical disc product on the development of adjacent level disease, whereas long-term complication rates with artificial discs remain unknown. The limited evidence on 4- to 5-year follow-up is inadequate to evaluate long-term results, in particular any effect of the device on adjacent level disc degeneration, device durability, adverse events, and revisions due to device malfunction. Longer term results are expected, given the FDA requirement for 7- to 10-year postapproval studies of the safety and function of the devices, and 5-to 10-year enhanced surveillance study of these discs to more fully characterize adverse events in a broader patient population. The longer follow-up is needed to better define the risk/benefit ratio of these devices.
Practice Guidelines and Position Statements
The 2011 guidelines from the North American Spine Society (NASS) on the diagnosis and treatment of cervical radiculopathy from degenerative disorders give a grade B recommendation that anterior cervical decompression with fusion and total disc arthroplasty are suggested as comparable treatments, resulting in similarly successful short-term outcomes, for single-level degenerative cervical radiculopathy.(44)
The United Kingdom’s National Institute for Health and Care Excellence (NICE) issued guidance on the artificial cervical disc in 2010. (45) NICE concluded that “current evidence on the efficacy of prosthetic intervertebral disc replacement in the cervical spine shows that this procedure is as least as efficacious as fusion in the short term and may result in a reduced need for revision surgery in the long term. The evidence raises no particular safety issues that are not already known in relation to fusion procedures. Therefore this procedure may be used provided that normal arrangements are in place for clinical governance, consent and audit. This procedure should only be carried out in specialist units where surgery of the cervical spine is undertaken regularly. NICE encourages further research into prosthetic intervertebral disc replacement in the cervical spine. Research outcomes should include long-term data on preservation of mobility, occurrence of adjacent segment disease and the avoidance of revision surgery.”
The 2009 guidelines from the American Association of Neurological Surgeons (AANS) address anterior cervical discectomy (ACD) and anterior cervical discectomy and fusion for the treatment of cervical degenerative radiculopathy and cervical spondylotic myelopathy. These guidelines do not address the artificial cervical disc.(46,47)
Medicare National Coverage
A search of the online Medicare National Database
(http://www.cms.gov/mcd/search.asp?from2=search.asp&) identified a national coverage decision on artificial intervertebral discs for the lumbar spine. There is no national coverage decision on artificial intervertebral discs for the cervical spine.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments 2007; Volume 22, Tab 12.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments 2009; Volume 24, Tab 3.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disease of the cervical spine. TEC Assessments 2011; Volume 26, Tab 5.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disk disease of the cervical spine. TEC Assessments 2013; (in press).
- Mummaneni PV, Burkus JK, Haid RW et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine 2007; 6(3):198-209.
- Goffin J, Van Calenbergh F, van Loon J et al. Intermediate follow-up after treatment of degenerative disc disease with the Bryan Cervical Disc Prosthesis: single-level and bi-level. Spine (Phila Pa 1976) 2003; 28(24):2673-8.
- Boselie TF, Willems PC, van Mameren H et al. Arthroplasty versus fusion in single-level cervical degenerative disc disease: a cochrane review. Spine (Phila Pa 1976) 2013; 38(17):E1096-107.
- U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Report of United States Clinical Study Results (G010188) -- Prestige® Cervical Disc System. 2006. Available online at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4243b1_02.pdf. Last accessed November, 2013.
- Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J Manipulative Physiol Ther 1991; 14(7):409-15.
- Burkus JK, Haid RW, Traynelis VC et al. Long-term clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. J Neurosurg Spine 2010; 13(3):308-18.
- Murrey D, Janssen M, Delamarter R et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. Spine J 2009; 9(4):275-86.
- U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. ProDisc-C Summary of safety and effectiveness data. 2007. Available online at:
http://www.accessdata.fda.gov/cdrh_docs/pdf7/p070001b.pdf. Last accessed November, 2013.
- Delamarter RB, Murrey D, Janssen ME. Results at 24 months from the prospective, randomized multicenter investigational device exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. SAS Journal 2010; 4:122-28.
- Zigler JE, Delamarter R, Murrey D et al. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. Spine (Phila Pa 1976) 2013; 38(3):203-9.
- Delamarter RB, Zigler J. Five-year Reoperation Rates, Cervical Total Disc Replacement versus Fusion, Results of a Prospective Randomized Clinical Trial. Spine (Phila Pa 1976) 2013; 38(9):711-7.
- Nabhan A, Ahlhelm F, Pitzen T et al. Disc replacement using Pro-Disc C versus fusion: a prospective randomised and controlled radiographic and clinical study. Eur Spine J 2007; 16(3):423-30.
- Heller JG, Sasso RC, Papadopoulos SM et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. Spine (Phila Pa 1976) 2009; 34(2):101-7.
- Sasso RC, Anderson PA, Riew KD et al. Results of cervical arthroplasty compared with anterior discectomy and fusion: four-year clinical outcomes in a prospective, randomized controlled trial. J Bone Joint Surg Am 2011; 93(18):1684-92.
- Riew KD, Buchowski JM, Sasso R et al. Cervical disc arthroplasty compared with arthrodesis for the treatment of myelopathy. J Bone Joint Surg Am 2008; 90(11):2354-64.
- Goffin J, van Loon J, Van Calenbergh F et al. A clinical analysis of 4- and 6-year follow-up results after cervical disc replacement surgery using the Bryan Cervical Disc Prosthesis. J Neurosurg Spine 2010; 12(3):261-9.
- Cheng L, Nie L, Zhang L et al. Fusion versus Bryan Cervical Disc in two-level cervical disc disease: a prospective, randomised study. Int Orthop 2009; 33(5):1347-51.
- Coric D, Nunley PD, Guyer RD et al. Prospective, randomized, multicenter study of cervical arthroplasty: 269 patients from the Kineflex|C artificial disc investigational device exemption study with a minimum 2-year follow-up: clinical article. J Neurosurg Spine 2011; 15(4):348-58.
- Hadley MN. The real value of cervical arthroplasty? J Neurosurg Spine 2011; 15(4):345-6; discussion 46-7.
- U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data: Mobi-C. 2013. Available online at:
http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110002b.pdf. Last accessed November, 2013.
- Davis RJ, Kim KD, Hisey MS et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial. J Neurosurg Spine 2013; 19(5):532-45.
- Huppert J, Beaurain J, Steib JP et al. Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. Eur Spine J 2011; 20(9):1417-26.
- Phillips FM, Lee JY, Geisler FH et al. A Prospective, randomized, controlled clinical investigation comparing PCM Cervical disc arthroplasty with anterior cervical discectomy and fusion: 2-year results from the US FDA IDE Clinical Trial. Spine (Phila Pa 1976) 2013; 38(15):E907-18.
- U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Summary of safety and effectiveness data: SECURE-C. 2012. Available online at:http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100003b.pdf. Last accessed November, 2013.
- Jawahar A, Cavanaugh DA, Kerr EJ, 3rd et al. Total disc arthroplasty does not affect the incidence of adjacent segment degeneration in cervical spine: results of 93 patients in three prospective randomized clinical trials. Spine J 2010; 10(12):1043-8.
- Nunley PD, Jawahar A, Kerr EJ, 3rd et al. Factors affecting the incidence of symptomatic adjacentlevel disease in cervical spine after total disc arthroplasty: 2- to 4-year follow-up of 3 prospective randomized trials. Spine (Phila Pa 1976) 2012; 37(6):445-51.
- Coric D, Cassis J, Carew JD et al. Prospective study of cervical arthroplasty in 98 patients involved in 1 of 3 separate investigational device exemption studies from a single investigational site with a minimum 2-year follow-up. Clinical article. J Neurosurg Spine 2010; 13(6):715-21.
- Coric D, Kim PK, Clemente JD et al. Prospective randomized study of cervical arthroplasty and anterior cervical discectomy and fusion with long-term follow-up: results in 74 patients from a single site. J Neurosurg Spine 2013; 18(1):36-42.
- Maldonado CV, Paz RD, Martin CB. Adjacent-level degeneration after cervical disc arthroplasty versus fusion. Eur Spine J 2011; 20 Suppl 3:403-7.
- Fan H, Wu S, Wu Z et al. Implant failure of Bryan cervical disc due to broken polyurethane sheath: a case report. Spine (Phila Pa 1976) 2012; 37(13):E814-6.
- Kurtz SM, Toth JM, Siskey R et al. The latest lessons learned from retrieval analysis of ultra-high molecular weight polyethylene, metal-on-metal, and alternative bearing total disc replacements. Semin Spine Surg 2011; 24(1):57-70.
- Tsermoulas G, Bhattathiri PS. Anterior migration of prosthesis following cervical arthroplasty. Br J Neurosurg 2013; 27(1):132-3.
- Nguyen NQ, Kafle D, Buchowski JM et al. Ceramic fracture following cervical disc arthroplasty: a case report. J Bone Joint Surg Am 2011; 93(22):e132(1-4).
- McAfee PC, Cappuccino A, Cunningham BW et al. Lower incidence of dysphagia with cervical arthroplasty compared with ACDF in a prospective randomized clinical trial. J Spinal Disord Tech 2010; 23(1):1-8.
- Chen J, Wang X, Bai W et al. Prevalence of heterotopic ossification after cervical total disc arthroplasty: a meta-analysis. Eur Spine J 2012; 21(4):674-80.
- Yi S, Kim KN, Yang MS et al. Difference in occurrence of heterotopic ossification according to prosthesis type in the cervical artificial disc replacement. Spine (Phila Pa 1976) 2010; 35(16):1556-61.
- Tu TH, Wu JC, Huang WC et al. Heterotopic ossification after cervical total disc replacement: determination by CT and effects on clinical outcomes. J Neurosurg Spine 2011; 14(4):457-65.
- Cavanaugh DA, Nunley PD, Kerr EJ, 3rd et al. Delayed hyper-reactivity to metal ions after cervical disc arthroplasty: a case report and literature review. Spine (Phila Pa 1976) 2009; 34(7):E262-5.
- Guyer RD, Shellock J, MacLennan B et al. Early failure of metal-on-metal artificial disc prostheses associated with lymphocytic reaction: diagnosis and treatment experience in four cases. Spine (Phila Pa 1976) 2011; 36(7):E492-7.
- Bono CM, Ghiselli G, Gilbert TJ et al. An evidence-based clinical guideline for the diagnosis and treatment of cervical radiculopathy from degenerative disorders. Spine J 2011; 11(1):64-72.
- National Institute for Health and Clinical Excellence (NICE). Prosthetic intervertebral disc replacement in the cervical spine. 2010. Available online at: http://publications.nice.org.uk/prostheticintervertebral-disc-replacement-in-the-cervical-spine-ipg341. Last accessed November, 2013.
- Matz PG, Holly LT, Groff MW et al. Indications for anterior cervical decompression for the treatment of cervical degenerative radiculopathy. J Neurosurg Spine 2009; 11(2):174-82.
- Mummaneni PV, Kaiser MG, Matz PG et al. Cervical surgical techniques for the treatment of cervical spondylotic myelopathy. J Neurosurg Spine 2009; 11(2):130-41.
|CPT||22856||Total disc arthroplasty (artificial disc), anterior approach, icluding discectomy with end plate preparation (including osteophytectomy for nerve root or spinal cord decompression and microdissection), single interspace; cervical|
|22858||Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)|
|22861||Revision including replacement for total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical|
|22864||Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical|
|0092T||Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), each additional interspace, cervical (List separately in addition to code for primary procedure) (code deleted 12/31/14)|
|0095T||Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace; cervical (List separately in addition to code for primary procedure)|
|0098T||Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace; cervical (List separately in addition to code for primary procedure)|
|0375T||Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), cervical, three or more levels (new code 01/01/15)|
|ICD-9 Diagnosis||Investigational for all codes.|
|ICD-9 Procedure||84.62||Insertion of total spinal disc prosthesis, cervical|
|84.66||Revision or replacement of artificial spinal disc prosthesis, cervical|
|ICD-10-CM (effective 10/1/15)||Investigational for all codes.|
|ICD-10-PCS (effective 10/1/15)||0RR30JZ||Open replacement of cervical vertebral disc with synthetic substitute|
|0RR50JZ||Open replacement of cervicothoracic vertebral disc with synthetic substitute|
BryanCervical Disc System
Disc Replacement, Intervertebral - Cervical
Intervertebral Disc Arthroplasty – Cervical
Prestige Cervical Disc System
ProDisc-C Total Disc Replacement
Spine Arthroplasty - Cervical
|10/10/2006||Add to Surgery section||New policy|
|12/13/07||Replace Policy||Policy updated with TEC Assessment and revised extensively. Reference list also revised extensively. No change to policy statement.|
|11/13/08||Replace policy||Policy updated with literature review; references 18-22 added; no change to policy statement;CPT coding updated|
|04/24/09||Replace policy||Policy updated with TEC Assessment. References 21-22 deleted, new references 18, 22-24 added. Policy statement unchanged. URLs updated|
|06/10/10||Replace policy||Policy updated with literature review through April 2010; references added and reordered; ACDF section moved to Description section and references removed. Policy statement unchanged|
|10/04/11||Replace policy||Policy updated with TEC Assessment and literature review through August 2011. References added and reordered; policy statement unchanged|
|9/13/12||Replace policy||Policy updated with literature review through June 2012; references added and reordered; policy statement unchanged|
|1/25/13||Replace polciy - local policy||artifical cervical disc considered med nec for specific criteria - TEC considers all investigational|
|1/09/14||Replace policy||Policy updated with literature review through November 20, 2013; references 4, 7, 14-15, 24-25, 27-28, 32, 36, 44, and 46-47 added and reordered; policy statement unchanged|
|1/2/15||coding update only||Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)|